Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis.

The prognostic value of chromogranin-A (CHGA) as a biomarker of prostate cancer (PCa) has been evaluated extensively. However, to date the results still remain controversial. This study aims to perform a meta-analysis on previous studies in order to determine whether CHGA would be a biomarker for survival in PCa patients. MEDLINE, Embase, Web of Science, and Cochrane Library databases were searched to identify eligible studies published before September 2018, regarding the association of gene expression with survival outcomes in patients with PCa. Multivariate adjusted HRs and associated 95% CIs were calculated using random effects models. Ten cohort studies involving 3,172 patients were finally included. According to the included studies, circulating CHGA levels were tested in serum, plasma, and tissues. The results showed an association between high CHGA expression and worse overall survival (OS) (HR=1.24, 95% CI: 1.07-1.44; =0.004; =77.6%) in PCa patients. However, no significant association was observed between increasing expression and shorter progression-free survival (HR=1.73, 95% CI: 0.92-3.28; =0.090; =73.9%). The results of sensitivity analysis validated the rationality and reliability of our analysis. Current evidence indicates that high CHGA expression is a potential marker for poor OS in PCa. Future studies are needed to explore tailored treatments that directly target for the improvement of survival in men with PCa.